LY96 and prostate adenocarcinoma: This clinical study (Metastatic Prostate Adenocarcinoma (SU2C/PCF Dream Team, PNAS) showed that cases with MD2 gene alterations tend to exhibit a worse overall survival (Log-rank Test p = 0.389) than cases who have no alterations (Fig. 1B).